Symbiodx And Cure Forward Partner To Advance Precision Medicine

Collaboration Designed to Improve Patient Connectivity and Clinical Trial Enrollment

SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Symbiodx, a leading molecular reference laboratory in the Pacific Northwest, and Cure Forward, a multisided technology platform to support patient engagement, today announced a new collaboration to advance precision medicine. The partnership between Symbiodx and Cure Forward will provide patients with streamlined access to their genomic data and greater exposure to relevant clinical trials.

“Bringing audiences together online is a type of innovation that has helped solve so many of life’s problems, from finding a ride to funding a startup. We decided to apply the same type of thinking to the challenge of complex disease”

“Symbiodx pathologists and staff are involved with the diagnosis and care of more than 10,000 cancer patients per year. We are very proud of the quality and service we provide to our patients and their treating physicians. Partnering with Cure Forward will allow us to provide an additional service to our cancer patients in helping them connect with clinical trials.” Anna Berry, M.D Director of Molecular Pathology at Symbiodx.

Symbiodx is an innovative, state-of-the-art anatomic and molecular pathology reference laboratory currently doing more than 300,000 biopsies annually. Symbiodx provides a unique solution for cancer genomics testing through a custom designed next generation sequencing (NGS) assay that incorporates the histopathology findings, and informs clinical decision-making for both solid and hematologic malignancies.

Cure Forward launched in private beta earlier this year to streamline the connection between diagnosed cancer patients and clinical trial administrators. Through Cure Forward’s website, patients can retrieve molecular diagnostic test results ordered by their physicians from accredited laboratory test providers, and then use that data to access educational information, collaborate with other patients, or investigate treatment options including clinical trials. With its unique clinical trial matching technology, inverts conventional approaches to trial matching by bringing trial invitations directly to patients. The solution is intended to reduce recruitment times and increase trial participation, to support faster approval of targeted therapies for cancer patients.

“Bringing audiences together online is a type of innovation that has helped solve so many of life’s problems, from finding a ride to funding a startup. We decided to apply the same type of thinking to the challenge of complex disease,” said Martin Naley, Cure Forward CEO. “At Cure Forward, cancer patients use their medical data to unlock insights and opportunities that may change the course of their care. It begins with high-quality test data from leading clinical diagnostic laboratories. We’re pleased to announce another step toward our goal to help patients with the collaboration between Cure Forward and Symbiodx.”

In addition to the clinical trial exchange, Cure Forward also offers access to educational information, starting in cancer, to help consumers understand the molecular science of their disease, as well as an online community where patients with the same molecular and clinical factors can connect and collaborate.

For more information about Symbiodx, please visit www.symbiodx.com and for more information about Cure Forward, visit www.CureForward.com.

About Symbiodx

Symbiodx is a national anatomic pathology and molecular oncology reference laboratory committed to helping pathologists and oncologists provide critical answers in treatment planning and improving patient outcomes. The company was formed in 2013 by PAML and CellNetix to provide esoteric testing and consultation services to pathology and oncology groups around the US. Symbiodx employs over 50 pathologists and provides comprehensive sub specialized anatomic and molecular pathology services at its central state-of-the-art clinical laboratory in Seattle. For more information, visit www.symbiodx.com.

About Cure Forward

Cure Forward is built on the desire to help patients identify and better understand relevant treatment options for their condition by bridging the gap for patients and precision medicine, beginning in cancer. Through our website, patients can become champions of their own care, work more effectively with care providers and make more informed choices toward the best treatment paths. As a multisided platform, the company overcomes inefficiencies that currently separate patients from the insights and options that can shape their care and support their treatment journey. Cure Forward solves critical business needs for its diagnostic laboratory, health care provider, and clinical trial partners, including the potential to fill trials more quickly through its unique clinical trial exchange. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, a leading healthcare venture capital firm headquartered in New York City.

Help employers find you! Check out all the jobs and post your resume.